Last reviewed · How we verify
Genexol®
Genexol is a paclitaxel-based nanoparticle formulation that delivers the chemotherapy agent to cancer cells while reducing systemic toxicity.
Genexol is a paclitaxel-based nanoparticle formulation that delivers the chemotherapy agent to cancer cells while reducing systemic toxicity. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Genexol® |
|---|---|
| Sponsor | Samyang Biopharmaceuticals Corporation |
| Drug class | Taxane chemotherapy (nanoparticle albumin-bound) |
| Target | Microtubule stabilization (paclitaxel mechanism) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Genexol uses albumin-bound nanoparticle technology to solubilize paclitaxel without Cremophor EL, improving drug delivery to tumors and reducing hypersensitivity reactions. The nanoparticles preferentially accumulate in tumor tissue through the enhanced permeability and retention (EPR) effect, allowing higher intratumoral concentrations while maintaining a better tolerability profile compared to conventional paclitaxel formulations.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Ovarian cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Fatigue
- Alopecia
Key clinical trials
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (PHASE1, PHASE2)
- Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas (PHASE2)
- A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (PHASE2)
- A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer (PHASE2)
- Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer (PHASE3)
- Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer (PHASE1)
- Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer (PHASE1)
- A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |